What will it take to eliminate drug-resistant tuberculosis?
Keywords: cost effectiveness; drug resistance; elimination; incidence reduction; prevention
Document Type: Research Article
Affiliations: 1: Johns Hopkins University, Baltimore, Maryland, USA 2: Stop TB Partnership, Geneva, Switzerland 3: McGill International TB Center, McGill University, Montreal, Quebec, Canada 4: Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia 5: Médecins Sans Frontières, Paris, France 6: Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; **Rollins School of Public Health, Emory University, Atlanta, Georgia, USA 7: AIDS and Rights Alliance for Southern Africa, Cape Town, South Africa 8: London School of Hygiene & Tropical Medicine, London, UK
Publication date: May 1, 2019
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content